BRAF and thyroid gland carcinoma: Another phase II clinical trial of nivolumab (a PD-1 inhibitor) is being conducted in metastatic radioiodine-resistant BRAF V600E-positive thyroid cancer (clinicaltrial.gov.in NCT04061980).